December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

220.87 +0.73 (+0.33%)
Streaming Delayed Price Updated: 12:08 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment ↗
Johnson & Johnson's stock approaches its 52-week high due to positive Phase 3 CAPLYTA trial data, strong earnings momentum, and favorable market sentiment as it nears an upcoming earnings report. 
Via Talk Markets
News headline image
How To Earn $500 A Month From Johnson &amp; Johnson Stock Ahead Of Q4 Earnings ↗
Johnson & Johnson (NYSE: JNJ) to release Q4 earnings on Jan. 21, with analysts expecting $2.47/share. Recent news includes positive results for cancer drug and dividend yield of 2.38%. 
Via Benzinga
News headline image
Option Volatility And Earnings Report For January 20 - 23
Earnings season ramps up this week with some big names set to report. This week we have Netflix, Intel, Johnson & Johnson, Freeport McMoran and 3M Company all reporting in what shapes as a busy and... 
Via Barchart.com
News headline image
Johnson &amp; Johnson&#39;s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4 ↗
Johnson & Johnson is set to report its Q4 results on Wednesday, facing one of the most important transitions in its modern history. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Stands Out as a Dependable Dividend Stock ↗
Via Chartmill
News headline image
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its... 
Via Finterra
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Income investors can rely on these stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street’s Comeback King: Citigroup Shatters M&A Records as Jane Fraser Sets a High Bar for 2026
Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Wall Street Renaissance: Goldman Sachs Posts Record $9.3 Billion in Fees as Dealmaking Roars Back
On January 15, 2026, Goldman Sachs (NYSE: GS) silenced critics of its strategic pivot by reporting a powerhouse fourth-quarter performance for 2025, headlined by a staggering $9.34 billion in annual... 
Via MarketMinute
Topics Credit Cards Earnings Economy
News headline image
Citigroup Shakes Up Wall Street with Record M&A Revenue as Global Dealmaking Thaws
In a definitive signal that the era of stagnant dealmaking has come to a close, Citigroup (NYSE:C) has reported record-breaking M&A advisory revenue for the fiscal year 2025. The results, unveiled on... 
Via MarketMinute
Topics Economy
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Johnson &amp; Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients ↗
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects. 
Via Benzinga
Topics Death
News headline image
Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
News headline image
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter... 
Via MarketMinute
Topics Bankruptcy
News headline image
US Current Account Deficit Narrows to $226.4 Billion in Q3 2025: An Analysis of the Shift
The United States current account deficit narrowed significantly in the third quarter of 2025, falling to $226.4 billion, or approximately 2.9% of the nation’s gross domestic product (GDP). This marks... 
Via MarketMinute
Topics Economy World Trade
News headline image
The 'Beautiful' Boom: How the 2025 Tax Overhaul is Fueling a 2026 Corporate Spending Spree
As the first quarter of 2026 unfolds, the American corporate landscape is undergoing a massive transformation, driven by the legislative shockwaves of the "One Big Beautiful Bill Act" (OBBBA) of July... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Court Orders Recalculation Of Damages In Johnson &amp; Johnson Auris Case ↗
Delaware's top court overturned part of a $1 billion damages award against Johnson & Johnson in the Auris Health merger, ordering a recalculation that could lower payouts. 
Via Benzinga
News headline image
The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New... 
Via PredictStreet
Topics Artificial Intelligence Bankruptcy Economy
News headline image
2 No-Brainer Dividend Stocks to Buy Right Now ↗
More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks. 
Via The Motley Fool
Topics World Trade
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio ↗
Add some stability to your holdings with these healthcare giants. 
Via The Motley Fool
Topics Economy Intellectual Property Lawsuit
News headline image
The Grinch Who Stole Wall Street: Santa Claus Rally Fails for Third Straight Year, Echoing 1950s Slump
As the final trading bell of January 5, 2026, echoed across the floor of the New York Stock Exchange, a chilling realization set in for market historians and retail investors alike: the legendary... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
Johnson &amp; Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts ↗
Johnson & Johnson struck a deal with the Trump administration to lower drug prices for U.S. consumers in exchange for exemptions from tariffs. 
Via Benzinga
Topics Government
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
From Johnson & Johnson
Via Business Wire
News headline image
Johnson’s Junk Removal Launches Full-Service Junk Removal in Kenmore
Via Get News
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.